转移性黑色素瘤免疫治疗患者的颅外放疗应用模式
基于美国国家癌症数据库2004–2013年1675例接受免疫治疗的颅外转移性黑色素瘤患者,分析颅外放疗的使用模式及其与总生存的关系。研究发现放疗使用率从2004年11.5%升至2013年19.8%(P=0.04),放疗联合免疫治疗组中位OS为15.4个月 vs 免疫治疗单药组19.4个月(P=0.02)。多因素分析中放疗与更差OS无关;不良OS仅限于骨转移放疗患者;软组织转移患者中免疫治疗前≥30天放疗OS优于30天内或后30天放疗。
要点
- 颅外放疗使用率及SBRT使用随时间增加,2004年11.5%升至2013年19.8%(P=0.04)。
- 多因素分析中颅外放疗与更差OS无关,不良OS局限于骨转移放疗患者。
- 软组织转移患者免疫治疗前≥30天放疗中位OS 26.1个月,优于30天内16.0个月(P=0.009)及后30天15.4个月(P=0.004)。
核心结论
- 颅外放疗在免疫治疗时代的转移性黑色素瘤管理中作用日益增加,放疗部位和时机可能与免疫治疗存在重要交互作用,需在未来临床试验中仔细考虑。
研究设计与样本
- 回顾性队列研究,数据来自美国国家癌症数据库,纳入2004至2013年接受免疫治疗(联合或不联合颅外放疗)的颅外转移性黑色素瘤患者1675例。
- 采用多因素Cox回归分析评估与总生存相关的因素,并比较骨转移与软组织转移放疗亚组结局,OS比较使用Kaplan-Meier和log-rank统计。
主要发现
- 共1675例患者,1387例仅接受免疫治疗,288例接受免疫治疗联合放疗。
- 放疗使用率从2004年11.5%(SBRT为0%)逐渐升至2013年19.8%(SBRT为27.0%)(P=0.04)。
- 免疫治疗联合放疗组与免疫治疗单药组中位OS分别为15.4个月与19.4个月(P=0.02)。
- 多因素分析中放疗与更差OS无关,不良OS局限于接受骨转移放疗的患者,软组织转移放疗患者中未见。
- 软组织转移放疗亚组中,免疫治疗前至少30天放疗的中位OS为26.1个月,优于免疫治疗30天内16.0个月(P=0.009)及免疫治疗后30天15.4个月(P=0.004)。
关键数值与推荐
- 放疗使用率:2004年11.5%(SBRT 0%),2013年19.8%(SBRT 27.0%),P=0.04。
- 中位OS:免疫治疗联合放疗组15.4个月 vs 免疫治疗单药组19.4个月,P=0.02。
- 软组织转移放疗时机与OS:免疫治疗前≥30天26.1个月 vs 免疫治疗30天内16.0个月(P=0.009) vs 免疫治疗后30天15.4个月(P=0.004)。
临床怎么用
- 在转移性黑色素瘤免疫治疗患者中,颅外放疗使用需考虑转移部位,骨转移放疗与更差OS相关而软组织转移未见此关联。
- 对软组织转移患者,若计划联合颅外放疗,免疫治疗前至少30天给予放疗可能与更高OS相关,需在前瞻性试验中验证。
局限性
- 为回顾性数据库研究,可能存在选择偏倚和未测量混杂因素。
- 数据来自2004至2013年,免疫治疗药物类型和放疗技术可能与当前实践不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Explore the patterns of use of extracranial radiation therapy (RT) in metastatic melanoma patients receiving immunotherapy, its potential association with OS, the impact of the site and timing of RT on clinical outcomes when combined with immunotherapy. MATERIALS AND METHODS: Patients with extracranial metastatic melanoma who received immunotherapy with or without extracranial RT from 2004 to 2013 were obtained from the National Cancer Database. Multivariable Cox regression analysis was used to evaluate factors associated with overall survival (OS). Subset analyses comparing outcomes in patients receiving RT to bone metastases versus soft tissue metastases were also performed. OS was compared using the Kaplan-Meier and log-rank statistics. RESULTS: A total of 1675 patients were identified: 1387 received immunotherapy alone and 288 received immunotherapy plus RT. An increase in the utilization of RT as well as SBRT was noted over time. The rate of RT use was 11.5% (0% with SBRT) in 2004 and gradually rose to 19.8% (27.0% with SBRT) in 2013 (P = 0.04). The median OS was 15.4 vs. 19.4 months in the immunotherapy plus RT and immunotherapy alone groups, respectively (P = 0.02). However, on multivariable analysis, RT was not associated with worse OS. The poor OS in the RT group was confined to the patients who received RT to bone metastases, but not in patients who received RT to soft tissue metastases. In subset analyses of patients irradiated to soft tissue, RT administered at least 30 days before immunotherapy was associated with a higher OS than RT administered within 30 days or 30 days after immunotherapy: median 26.1 months vs. 16.0 months (P = 0.009) vs. 15.4 months (P = 0.004), respectively. CONCLUSIONS: This study demonstrates that extracranial RT plays an increasing role in the management of metastatic melanoma patients in the era of immunotherapy. The site and the timing of RT may have important interaction with immunotherapy, and need to be carefully considered in future clinical trials.
引用
- Gabani P, Robinson CG, Ansstas G, et al. Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy. Radiother Oncol. 2018. PMID: 29534829. doi:10.1016/j.radonc.2018.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。